ReviewPharmaceuticals (Basel, Switzerland)2023
Interplay of Gut Microbiota in Polycystic Ovarian Syndrome: Role of Gut Microbiota, Mechanistic Pathways and Potential Treatment Strategies.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Pooled it
- Polycystic ovary syndrome in obstructive sleep apnea-hypopnea syndrome: an updated meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Acupuncture for hormonal readiness and gut microbiota in obese polycystic ovary syndrome: an open-label, randomized controlled trial.Frontiers in endocrinology · 2024Trial
- The cervicovaginal gut microbiota axis as a key determinant of systemic physiology.Gut microbes · 2026Review
- Polyendocrine Metabolic Ovarian Syndrome (PMOS; Formerly Polycystic Ovary Syndrome/PCOS) and Susceptibility to Microbial Infections: Mechanisms, Clinical Management, and Reproductive Consequences - A Comprehensive Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Epigenetic regulation of ovarian steroidogenesis in PCOS: HDAC inhibitors and short-chain fatty acids.Molecular biology reports · 2026Review
- Targeting the gut-ovarian axis:mSystems · 2026Article
- Algae-Derived Bioactives Reprogram the Gut-SIRT1-Kisspeptin Axis in Polycystic Ovary Syndrome.Marine drugs · 2026Review
- Microbial Dysbiosis and Pathogenic Interplay in the Gut-Vaginal Axis: Implications for Polycystic Ovary Syndrome: A Critical Review.Current microbiology · 2026Review
- A Roadmap for Advancing Women's Health in Disorders of the Gut-Brain Interaction.United European gastroenterology journal · 2026Review
- The gut microbiome in polycystic ovary syndrome: mechanistic pathways and therapeutic potential of microbiota-targeted interventions.Frontiers in endocrinology · 2026Review
- Gut microbiota and polyendocrine metabolic ovarian syndrome: an integrated gut-metabolism-endocrine-ovary axis.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- The gut microbiota-metabolite axis in polycystic ovary syndrome: differential characteristics between infertile and conceived populations.Frontiers in microbiology · 2026Article
- The role of intestinal microbial metabolites in polycystic ovary syndrome: mechanistic insights and intervention prospects.Frontiers in endocrinology · 2026Review
- Therapeutic perspective of postbiotics in managing health of women with polycystic ovarian syndrome: a holistic approach.Inflammopharmacology · 2025Review
- The Effects of a Novel Fortified Dairy Product on Weight Loss, Metabolic Profiles, and Endocrine Hormones in Women With Polycystic Ovary Syndrome: A Double-Blind Randomized Controlled Trial.Food science & nutrition · 2025Article
- Harnessing Microbiome, Bacterial Extracellular Vesicle, and Artificial Intelligence for Polycystic Ovary Syndrome Diagnosis and Management.Biomolecules · 2025Review
- Body image disturbances in women of childbearing age with polycystic ovary syndrome: a cross-sectional study.BMC women's health · 2025Article
- Therapeutic potential of microbiome modulation in reproductive cancers.Medical oncology (Northwood, London, England) · 2025Review
- Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic Ovarian Syndrome (PCOS) comprises a set of symptoms that pose significant risk factors for various diseases, including type 2 diabetes, cardiovascular disease, and cancer. Effective and safe methods to treat all the pathological symptoms of PCOS are not available. The gut microbiota has been shown to play an essential role in PCOS incidence and progression. Many dietary plants, prebiotics, and probiotics have been reported to ameliorate PCOS. Gut microbiota shows its effects in PCOS via a number of mechanistic pathways including maintenance of homeostasis, regulation of lipid and blood glucose levels. The effect of gut microbiota on PCOS has been widely reported in animal models but there are only a few reports of human studies. Increasing the diversity of gut microbiota, and up-regulating PCOS ameliorating gut microbiota are some of the ways through which prebiotics, probiotics, and polyphenols work. We present a comprehensive review on polyphenols from natural origin, probiotics, and fecal microbiota therapy that may be used to treat PCOS by modifying the gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.